Company
Every investor coverage indicates participated in a round Kalaris Therapeutics raised.
Companies Kalaris Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Elizabeth Cermak | Board Member | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Kalaris Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Aravax, developer of the peanut allergy immunotherapy PVX108, adds former ALK-Abello chief Carsten Hellmann and ex-Aimmune commercial head Andrew Oxtoby to its board ahead of Phase 3.
Biotech company QUE Oncology adds two experienced pharmaceutical executives, Julie Cherrington and Elizabeth Cermak, to its board as it develops a non-hormonal breast cancer therapy.
Clinical-stage biotech QUE Oncology adds two experienced life science executives, Julie Cherrington and Elizabeth Cermak, to its board, while continuing trials of its non-hormonal therapy for breast cancer hot flashes.